The Macrophage Activation Marker Soluble CD163 Predicts the Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma
IP was associated with Atez/Bev response in HCC. sCD163 could be a predictive marker of Atez/Bev response in patients with aHCC.
Authors
- Kiyoshi Asada (ORCID: https://orcid.org/0000-0002-4515-6047)
- Hitoshi Yoshiji (ORCID: https://orcid.org/0000-0002-5243-8544)
- Akira Mitoro
- Takashi Inoue (ORCID: https://orcid.org/0000-0002-9672-2117)
- Koh Kitagawa (ORCID: https://orcid.org/0000-0001-5794-1512)
- Atsushi Koizumi
- Tadashi Namisaki (ORCID: https://orcid.org/0000-0002-3158-5318)
- Hiroaki Takaya (ORCID: https://orcid.org/0000-0002-4990-7573)
- Soichi Takeda (ORCID: https://orcid.org/0000-0001-9494-9062)
- Satoshi Iwai (ORCID: https://orcid.org/0000-0003-3575-5609)
- Akihiko Shibamoto
- Norihisa Nishimura (ORCID: https://orcid.org/0000-0002-6295-3283)
- Shinya Sato (ORCID: https://orcid.org/0000-0002-5978-0975)
- Kosuke Kaji (ORCID: https://orcid.org/0000-0002-1822-6759)
- Yukihisa Fujinaga (ORCID: https://orcid.org/0000-0003-2402-574X)
- Yuki Tsuji
Institutions
- Nara Medical University (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-09-26
- DOI
- https://doi.org/10.21873/anticanres.17797
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00